Summary & Overview
CPT 89325: Sperm Antibody Test for Infertility Diagnosis
Headline: Newborn of an infertility diagnostic test: CPT 89325 and its role in reproductive medicine
Lead: CPT 89325 is a specialized laboratory test that detects sperm antibodies in semen or serum to help diagnose immunologic causes of infertility. The code represents a targeted diagnostic service in reproductive medicine with implications for fertility evaluation and treatment planning nationwide.
What this code represents and why it matters: CPT 89325 identifies a laboratory assay used when immune-related infertility is suspected. As reproductive services and fertility evaluations expand, this code matters for accurate claims, clinical documentation, and care pathway selection for patients undergoing infertility workups.
Key payers covered: The analysis covers major commercial payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
What readers will learn: The publication provides a concise overview of the clinical context and typical laboratory setting for CPT 89325, explains relevant diagnosis linkage, and situates the test among related semen and sperm-function assays. It outlines common billing considerations such as professional versus technical reporting components and references adjacent laboratory codes used in fertility evaluation. The piece also highlights where input data are complete and notes when specific service-line metadata are not available.
Scope: The summary is written for a national audience of billing professionals, laboratory managers, and clinicians involved in reproductive medicine. Data not available in the input are identified explicitly in the detailed sections.
CPT Code Overview
CPT 89325 describes a laboratory procedure in which a lab analyst measures sperm antibodies in a biological sample (for example, male semen or female serum) to evaluate causes of infertility. This test is classified under Reproductive Medicine Procedures (Laboratory) and is typically performed in a clinical laboratory setting, such as an independent reference lab or a hospital laboratory.
Clinical & Coding Specifications
Clinical Context
A 34-year-old couple presents to a reproductive medicine clinic after 12 months of unsuccessful conception. The male partner provides a semen specimen and the female partner has a serum sample collected during initial infertility evaluation. The laboratory performs an assay to detect sperm antibodies in the provided specimens to evaluate immunologic causes of infertility. Results are returned to the referring obstetrics/gynecology or family medicine physician and the clinical pathologist for interpretation and inclusion in the fertility workup. Typical workflow: specimen collection in clinic or by the patient, transport to the clinical laboratory, technical testing (may be billed as the technical component), and professional review and reporting by the lab analyst or pathologist (may be billed as the professional component).
Coding Specifications
-
Modifier
26: Professional component. Use when only the professional interpretation or reporting portion of the test is provided by the billing clinician (e.g., pathologist review and report) and the technical testing is performed by another entity. -
Modifier
TC: Technical component. Use when only the technical portion of the test (specimen processing, reagent use, instrumentation) is provided by the billing facility or laboratory and professional interpretation is not included.
Provider Taxonomies
| Taxonomy Code | Specialty |
|---|---|
207ZP0102X | Pathology - Clinical Pathology/Laboratory Medicine |
207Q00000X | Family Medicine Physician |
207V00000X | Obstetrics & Gynecology Physician |
Related Diagnoses
-
N46.9— Male infertility, unspecifiedRelevance: Male infertility is a primary indication for sperm antibody testing to identify immunologic factors that may impair sperm function.
-
N97.9— Female infertility, unspecifiedRelevance: Female infertility evaluation may include assessment of male partner antibodies or female serum antibodies affecting sperm, making
89325relevant when both partners are tested. -
Z31.41— Encounter for fertility testingRelevance: Represents the clinical encounter during which diagnostic tests such as sperm antibody assays (
89325) are ordered and performed. -
Z31.49— Encounter for other procreative managementRelevance: Used for visits addressing broader fertility management where immunologic testing like
89325may be part of the diagnostic panel. -
R87.8— Other specified abnormal findings of blood chemistryRelevance: Abnormal serologic findings related to antibodies or other blood chemistry abnormalities may prompt or be identified by tests including sperm antibody assays.
Related CPT Codes
| CPT Code | Description |
|---|---|
89321 | Semen analysis & motility |
89329 | Per Codify: The lab analyst performs a test to evaluate whether sperm can penetrate a hamster egg to diagnose infertility. |
89330 | The lab analyst performs the technical lab test to analyze sperm using a cervical mucus penetration test. This test may or may not include a spinnbarkeit test to test the elasticity of the cervical mucus. |
-
89321is commonly performed as an initial laboratory assessment of male fertility and may precede or accompany89325when antibody-mediated impairment is suspected. -
89329is a functional penetration assay that assesses sperm capacity to penetrate an egg; it may be ordered in parallel or as a subsequent specialized test when basic parameters and antibody testing (89325) do not fully explain infertility. -
89330evaluates sperm interaction with cervical mucus and may be used alongside89325when assessing immunologic and functional causes of impaired sperm-cervical mucus interaction. -
These related tests can be used together in a comprehensive infertility laboratory workup or as alternatives depending on clinical findings and provider ordering patterns.
National Reimbursement Benchmarks
National mean rates for CPT 89325 show that Medicare is lower than the BUCA (average commercial) mean: BUCA’s mean of $11.39 exceeds Medicare’s mean ($0.00 in the input). Blue Cross Blue Shield and Cigna report the highest commercial means at $12.94 and $14.80 respectively, while Aetna and UnitedHealth Group have means near $8.92.
Rate dispersion (P75 minus P25) varies across payers. Cigna shows one of the widest spreads (approximately $9.67), indicating broader variability around the median, while Aetna’s spread is tighter (about $3.25). UnitedHealth Group also shows moderate dispersion (~$5.33). The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.